Medical Decision Making

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Register here to gain access to SAGE's 500+ Journals Online

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Warren, E.
Right arrow Articles by Akehurst, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Warren, E.
Right arrow Articles by Akehurst, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Medical Decision Making, Vol. 24, No. 1, 9-19 (2004)
DOI: 10.1177/0272989X03261565

Cost-Effectiveness of Sibutramine in the Treatment of Obesity

Emma Warren

Alan Brennan

Operational Research, ScHARR, 30 Regent Street, Sheffield, S1 4DA, UK; a.brennan{at}sheffield.ac.uk

Ron Akehurst

Background.This study reports incremental cost-utility of sibutramine compared to diet and lifestyle advice for the treatment of obesity.Method.The model estimates the costs and quality of life benefits associated with weight loss itself and the reduced incidence of coronary heart disease (CHD) and diabetes in the "healthy obese." The key source of effectiveness data is 2 randomized controlled trials over 12 months. Utility gain per kilogram lost is analyzed using Short Form–36 data from sibutramine trials. The impact on CHD is estimated using the Framingham risk equation, which relates age/sex/body mass index to risk of heart disease. The reduced incidence of diabetes due to weight loss is estimated from published literature. A life tables approach was used to calculate the cost per quality-adjusted life year (QALY) of 1 year’s treatment with sibutramine compared to diet and lifestyle advice.Results.The incremental cost per QALY of sibutramine is £4780. Sensitivity analyses show that this result is sensitive to utility associated with weight loss and the frequency of monitoring.Conclusions. Sibutramine is a costeffective treatment for obesity when combined with diet and lifestyle advice.

Key Words: cost-utility • obesity • model • sibutramine


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Chronic IllnessHome page
L. Gordon, N. Graves, A. Hawkes, and E. Eakin
A review of the cost-effectiveness of face-to-face behavioural interventions for smoking, physical activity, diet and alcohol
Chronic Illness, June 1, 2007; 3(2): 101 - 129.
[Abstract] [PDF]